Compare Regeneron Pharmaceuticals Inc (REGN) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Xpeng Inc - ADR — how do they compare? Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B), while Xpeng Inc - ADR trades at $10.66 (market cap $10.34B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 8.1× Xpeng Inc - ADR's market cap, and Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals.
| REGN | XPEV | |
|---|---|---|
Market Cap | $83.43B | $10.34B |
Sector | Health | Consumer Cyclical |
52-Week High | $852.03 | $28.07 |
52-Week Low | $555.51 | $10.57 |
Enterprise Value | $78.14B | $12.92B |
Dividend Yield | 0.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
XPeng (XPEV) trades at $10.93, down 0.18% on the day, with a bearish technical signal and negative earnings in recent quarters. The company reported a net loss of $1.14 billion in 2025 despite revenue growth to $76.72 billion, and cash flow trends show volatility. Recent news highlights expansion into humanoid robotics, with the robotics unit raising over $900 million at a $6.3 billion valuation in August 2026.
The outlook is mixed: analyst consensus is bullish with a $19.00 price target, but execution risks in the competitive EV market and persistent losses pose challenges. Robotics diversification offers long-term potential, yet near-term profitability remains uncertain amid weak delivery forecasts and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
